{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:30:08Z","timestamp":1794961808595,"version":"4.9.1"},"reference-count":47,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2\u2010mediated inflammatory disease associated with significant clinical, social, and economic burdens and high unmet therapeutic need. Dupilumab, a fully human monoclonal antibody targeting the interleukin\u20104 receptor \u03b1 (IL\u20104R\u03b1) subunit, demonstrated efficacy and acceptable safety in CRSwNP and other type 2 diseases (eg, atopic dermatitis and asthma). We now report the local effects of dupilumab on type 2 inflammatory biomarkers in nasal secretions and nasal polyp tissues of patients with CRSwNP in a randomized, placebo\u2010controlled, phase 2 trial (NCT01920893).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cytokines, chemokines, and total immunoglobulin E (IgE) levels were measured using immunoassay techniques in nasal secretions and nasal polyp tissue homogenates of CRSwNP patients receiving dupilumab 300\u00a0mg or placebo weekly for 16\u00a0weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      With dupilumab, type 2 biomarker concentrations decreased in nasal secretions (least squares mean area under the curve from 0 to 16\u00a0weeks for the change from baseline) vs placebo for eotaxin\u20103 (\u221230.06 vs \u22120.86\u00a0pg\/mL;\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.0008) and total IgE (\u22127.90 vs \u22121.86\u00a0IU\/mL;\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.022). Dupilumab treatment also decreased type 2 biomarker levels in nasal polyp tissues at Week 16 vs baseline for eosinophilic cationic protein (\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.008), eotaxin\u20102 (\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.008), eotaxin\u20103 (\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.031), pulmonary and activation\u2010regulated chemokine (\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.016), IgE (\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.023), and IL\u201013 (\n                      <jats:italic>P\u00a0<\/jats:italic>\n                      =\n                      <jats:italic>\u00a0<\/jats:italic>\n                      0.031).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dupilumab treatment reduced multiple biomarkers of type 2 inflammation in nasal secretions and polyp tissues of patients with CRSwNP, demonstrating that antagonism of IL\u20104R\u03b1 signaling suppresses IL\u20104\u2010\/IL\u201013\u2010dependent processes, such as mucosal IgE formation, as well as the expression of chemokines attracting inflammatory cells to the nasal mucosa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/all.13685","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T20:39:52Z","timestamp":1543437592000},"page":"743-752","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":161,"title":["Dupilumab reduces local type 2 pro\u2010inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis"],"prefix":"10.1111","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0545-8008","authenticated-orcid":false,"given":"Karin","family":"Jonstam","sequence":"first","affiliation":[{"name":"Division of ENT Diseases Department of Clinical Sciences, Intervention and Technology Karolinska Institute Stockholm Sweden"},{"name":"Department of Ear, Nose and Throat Diseases Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian N.","family":"Swanson","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leda P.","family":"Mannent","sequence":"additional","affiliation":[{"name":"Sanofi Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-9580","authenticated-orcid":false,"given":"Lars\u2010Olaf","family":"Cardell","sequence":"additional","affiliation":[{"name":"Division of ENT Diseases Department of Clinical Sciences, Intervention and Technology Karolinska Institute Stockholm Sweden"},{"name":"Department of Ear, Nose and Throat Diseases Karolinska University Hospital Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Tian","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunpeng","family":"Fan","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Holtappels","sequence":"additional","affiliation":[{"name":"Upper Airways Research Laboratory Ghent University Hospital Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer D.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Grabher","sequence":"additional","affiliation":[{"name":"Sanofi Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M. H.","family":"Graham","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pirozzi","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-1665","authenticated-orcid":false,"given":"Claus","family":"Bachert","sequence":"additional","affiliation":[{"name":"Division of ENT Diseases Department of Clinical Sciences, Intervention and Technology Karolinska Institute Stockholm Sweden"},{"name":"Department of Ear, Nose and Throat Diseases Karolinska University Hospital Stockholm Sweden"},{"name":"Upper Airways Research Laboratory Ghent University Hospital Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02646.x"},{"key":"e_1_2_10_3_1","first-page":"743","article-title":"EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists","volume":"50","author":"Fokkens WJ","year":"2012","journal-title":"Rhinology"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1324"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-013-2395-2"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.112374"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01225.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.07.049"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201212-2227OC"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12462"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.07.008"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e3283448808"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2015.96"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02838.x"},{"issue":"1075","key":"e_1_2_10_15_1","first-page":"1083.e1","article-title":"Chronic rhinosinusitis with nasal polyps is characterized by B\u2010cell inflammation and EBV\u2010induced protein 2 expression","volume":"131","author":"Hulse KE","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2014.28.4033"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.10.010"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1010517"},{"issue":"110","key":"e_1_2_10_19_1","first-page":"e1","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert P","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1024","key":"e_1_2_10_20_1","first-page":"e14","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: a randomised trial","volume":"140","author":"Bachert C","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"599","key":"e_1_2_10_21_1","first-page":"vi","article-title":"Anti\u2010interleukin\u20104 therapy","volume":"24","author":"Steinke JW","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36130"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(01)00308-9"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.10.6286"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1323896111"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324022111"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4624"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16156"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19330"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.152835"},{"issue":"989","key":"e_1_2_10_35_1","first-page":"e1","article-title":"Mepolizumab, a humanized anti\u2010IL\u20105 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert P","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin16.314"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-10"},{"key":"e_1_2_10_38_1","first-page":"1253","article-title":"An overlook to the characteristics and roles played by eotaxin network in the pathophysiology of food allergies: allergic asthma and atopic dermatitis","volume":"39","author":"Ahmadi Z","year":"2016","journal-title":"Inflammation"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.4049\/jimmunol.162.5.2477","article-title":"Effects of Th2 cytokines on chemokine expression in the lung: IL\u201013 potently induces eotaxin expression by airway epithelial cells","volume":"162","author":"Li L","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.2500\/ajr.2008.22.3136"},{"key":"e_1_2_10_41_1","first-page":"145","article-title":"Eosinophilic nasal polyps are a rich source of eotaxin, eotaxin\u20102 and eotaxin\u20103","volume":"44","author":"Olze H","year":"2006","journal-title":"Rhinology"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636112"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.24.6.4301"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26679"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.03.017"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.08.021"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1204712"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.10.013"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fall.13685","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.13685","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/all.13685","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.13685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T15:44:56Z","timestamp":1694360696000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.13685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1111\/all.13685"],"URL":"https:\/\/doi.org\/10.1111\/all.13685","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,21]]},"assertion":[{"value":"2018-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}